时珍国医国药2025，Vol.36Issue(14)：2607-2613,7.DOI:10.70976/j.1008-0805.SZGYGY-2025-1402
疏肝和胃方对反流性食管炎大鼠PAR-2/P38MAPK通路影响的研究
Exploring the mechanism of Shugan Hewei Decoction(疏肝和胃方)in treating rats with re-flux esophagitis via the PAR-2/P38MAPK pathway
摘要
Abstract
Objective To investigate the effects of Shugan Hewei Decoction(疏肝和胃方,SGHWD)on the expressions of inflammatory factors IL-6,IL-1β,and TNF-α,and its inhibitory action on inflammation in a rat model of reflux esophagitis(RE)based on the PAR-2/P38MAPK signaling pathway.Methods Sixty SD rats were randomly divided into six groups:the sham-operated group,model group,low/medium/high-dose SGHWD groups,and rabeprazole group,with 10 rats in each group.Except for the sham group,the model of RE was established by lower esophageal sphincterotomy and duodenal hemiligature ligation.Rats in each group received daily gavage treatment for 2 weeks.After the final administration,histopathological changes in the esophageal tissues were examined using he-matoxylin-eosin(HE)staining.Immunohistochemistry(IHC)and Western blot(WB)were used to detect the expression levels of PAR-2 and P38MAPK proteins in the esophageal tissues.The serum levels of inflammatory factors IL-6,IL-1β,and TNF-α were measured by ELISA.Results Compared with the model group,the degrees of lesions in the low/medium/high-dose groups of SGHWD were alleviated.The ratio of PAR-2 to p-P38MAPK/P38MAPK in the esophageal tissues of these groups was significantly decreased(P<0.05),and the levels of inflammatory factors such as IL-6,IL-1β,and TNF-α were markedly reduced.Conclusion SGHWD may inhibit the progression of RE in rats by modulating the PAR-2/P38MAPK signaling pathway.关键词
反流性食管炎/疏肝和胃方/蛋白酶激活受体2/P38MAPKKey words
Reflux esophagitis/Shugan Hewei Decoction(疏肝和胃方)/PAR-2/P38MAPK分类
医药卫生引用本文复制引用
王玮,孙永顺..疏肝和胃方对反流性食管炎大鼠PAR-2/P38MAPK通路影响的研究[J].时珍国医国药,2025,36(14):2607-2613,7.基金项目
国家自然科学基金(81874402 （）
82174128) （）
上海市中医医院青年名中医项目(WLJH2021ZY-MZY032) （WLJH2021ZY-MZY032）
上海市中医医院未来计划项目(WL-HBBD-2021003K) （WL-HBBD-2021003K）
